Table 3. Treatment of CRS and ICANS with... | American Society of Hematology

Table 3.

Treatment of CRS and ICANS with siltuximab

	At siltuximab administration	Improvement after siltuximab, %	Median days to resolution (range)
CRS
Treatment-naïve	28	82 (23/28)	1 (0-7)
Tocilizumab-exposed∗	16	63 (10/16)	2 (0-4)
Total	44	75 (33/44)
ICANS
Treatment-naïve†	13	69 (9/13)	3 (1-13)
Steroid-exposed‡	17	53 (9/17)	5 (2-40)
Total	30	60 (18/30)

	At siltuximab administration	Improvement after siltuximab, %	Median days to resolution (range)
CRS
Treatment-naïve	28	82 (23/28)	1 (0-7)
Tocilizumab-exposed∗	16	63 (10/16)	2 (0-4)
Total	44	75 (33/44)
ICANS
Treatment-naïve†	13	69 (9/13)	3 (1-13)
Steroid-exposed‡	17	53 (9/17)	5 (2-40)
Total	30	60 (18/30)

Patients who received ≥1 doses of tocilizumab before siltuximab.

Includes patients who received steroids at the same time as siltuximab or after siltuximab.

Patients who received steroids for treatment of ICANS before siltuximab.